Nguyen and Thalmann review the benefits and disadvantages of the use of neoadjuvant chemotherapy in patients with bladder cancer, highlighting how clinical and molecular data can aid in personalizing treatment decisions, and discuss possible future application of targeted therapies and immune checkpoint inhibitors in this setting.
- Daniel P. Nguyen
- George N. Thalmann